AICDA: A Potential Drug Target for Genetic Disorders (G57379)

Target Name: AICDA

NCBI ID: G57379

AICDA

AICDA: A Potential Drug Target for Genetic Disorders

AICDA, or cytidine aminohydrolase, is a enzyme that is involved in the DNA replication process in the cell. It plays a crucial role in the maintenance of genetic accuracy by ensuring that the double helix is replicated faithfully. Mutations in the AICDA gene have been linked to a range of genetic disorders, including cancer, neurodegenerative diseases, and developmental delays. As a result, AICDA has become an attractive drug target for researchers and pharmaceutical companies.

The discovery of AICDA as a drug target was made through a combination of biochemical, genetic, and computational approaches. The AICDA gene was identified through DNA sequencing and analysis of cDNA libraries from a variety of organisms. The gene was then confirmed by bioinformatics analysis and physical validation through Southern blotting and gene expression studies.

AICDA is a protein that consists of 1,864 amino acids and has a calculated molecular mass of 21 kDa. It is a single-stranded DNA enzyme that catalyzes the hydrolysis of the nucleotide dTTP to form a phosphate and a nucleotide monophosphate. This reaction is essential for the initiation of DNA replication at the replication fork.

AICDA is a key enzyme in the DNA replication process because it ensures that the double helix is replicated in the correct order and that any mutations or alterations in the DNA are accurately copied. This is critical for the development and maintenance of an accurate genetic legacy.

Mutations in the AICDA gene have been linked to a range of genetic disorders. For example, a missense mutation has been linked to the neurodegenerative disease, frontotemporal dementia, in the AICDA gene. This mutation has been shown to cause the misfolding of AICDA and lead to the formation of aggregates that cause neurotoxicity.

Another study has also shown that mutations in the AICDA gene have been linked to the development of cancer. This is because AICDA is involved in the DNA replication process, which is critical for the development and progression of cancer.

In addition to its role in the DNA replication process, AICDA has also been shown to play a role in cell signaling and inflammation. It has been shown to be involved in the regulation of cell growth and in the production of pro-inflammatory cytokines.

The potential therapeutic benefits of AICDA as a drug target are significant. If AICDA were to be developed into a drug, it could be used to treat a variety of genetic disorders, including cancer, neurodegenerative diseases, and developmental delays.

AICDA has also been shown to be a promising biomarker for a variety of diseases. For example, AICDA levels have been shown to be elevated in the brains of individuals with frontotemporal dementia, a neurodegenerative disease. This suggests that AICDA may be a useful biomarker for the diagnosis and progression of this disease.

In addition, AICDA has also been shown to be involved in the regulation of cell signaling and inflammation. This suggests that it may be a useful target for the treatment of a variety of inflammatory and neurodegenerative disorders.

Overall, AICDA is a protein that plays a crucial role in the DNA replication process and has been linked to a range of genetic disorders. As a result, it is an attractive drug target for researchers and pharmaceutical companies. Further research is needed to fully understand the role of AICDA in the development and treatment of genetic disorders.

Protein Name: Activation Induced Cytidine Deaminase

Functions: Single-stranded DNA-specific cytidine deaminase. Involved in somatic hypermutation (SHM), gene conversion, and class-switch recombination (CSR) in B-lymphocytes by deaminating C to U during transcription of Ig-variable (V) and Ig-switch (S) region DNA. Required for several crucial steps of B-cell terminal differentiation necessary for efficient antibody responses (PubMed:18722174, PubMed:21385873, PubMed:21518874, PubMed:27716525). May also play a role in the epigenetic regulation of gene expression by participating in DNA demethylation (PubMed:21496894)

The "AICDA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AICDA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets